William Blair analyst Margaret Kaczor has maintained their bullish stance on PODD stock, giving a Buy rating today.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Margaret Kaczor has given her Buy rating due to a combination of factors driving Insulet’s positive outlook. The company reported impressive fourth-quarter results, with sales reaching $597.5 million, surpassing expectations by about $15 million. This performance was bolstered by robust growth in both the U.S. and international markets for their Omnipod product, as well as strong drug delivery sales. The impressive earnings per share beat, largely due to superior gross margins, further underpins her confidence in the company’s financial health.
Furthermore, the growth in new customer starts and the expanding installed base, now at 500,000 users, demonstrate a strong market presence and potential for future growth. The ongoing commercial expansion to support the type 2 product launch, alongside advancements with Automated Insulin Delivery (AID) systems, suggests a favorable setup for 2025. Kaczor sees multiple avenues for growth, cementing her view that Insulet is well-positioned for continued outperformance in both type 1 and type 2 markets.
According to TipRanks, Kaczor is a 4-star analyst with an average return of 7.9% and a 50.00% success rate. Kaczor covers the Healthcare sector, focusing on stocks such as Staar Surgical, Inari Medical, and CVRx.
In another report released today, Canaccord Genuity also maintained a Buy rating on the stock with a $324.00 price target.